Semaglutide for Weight Loss: Complete Guide to GLP-1 Therapy in 2026

Semaglutide has fundamentally changed the conversation around medical weight loss. Originally developed for type 2 diabetes under the brand name Ozempic, its weight management formulation (Wegovy) demonstrated such striking results in clinical trials that it’s become one of the most prescribed medications in the country.

But behind the headlines and social media buzz, there’s real science—and real considerations—that anyone thinking about semaglutide should understand before starting treatment.

How semaglutide works

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the action of glucagon-like peptide-1 (GLP-1), a hormone your body naturally produces after eating. GLP-1 does three key things: it signals your pancreas to produce insulin, it slows the rate at which food leaves your stomach (gastric emptying), and it acts on appetite centers in the brain to reduce hunger.

What makes semaglutide particularly effective is its engineered half-life. Natural GLP-1 is broken down by your body within minutes. Semaglutide has been modified to last roughly a week, which is why it’s administered as a once-weekly injection. This sustained activity provides consistent appetite suppression and metabolic benefits throughout the week.

Clinical results

The clinical data behind semaglutide is among the strongest for any weight loss intervention. The landmark STEP 1 trial showed an average weight loss of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. For someone weighing 220 pounds, that’s roughly 33 pounds.

Subsequent trials (STEP 2 through STEP 5) confirmed these results across different populations, including people with type 2 diabetes, those who had previously tried other weight loss interventions, and in maintenance settings. The SELECT trial additionally showed a 20% reduction in major cardiovascular events, which led to expanded FDA indications.

It’s worth noting that results vary significantly between individuals. Some patients lose considerably more than the average, while others may see more modest results. Factors like adherence to lifestyle modifications, starting weight, metabolic health, and genetics all play a role.

What to expect: the dose titration process

Semaglutide isn’t started at its full dose. Treatment follows a gradual titration schedule, typically starting at 0.25 mg weekly and increasing monthly through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg. This slow ramp-up is critical for minimizing gastrointestinal side effects.

Most patients begin noticing appetite changes within the first 1–2 weeks. Significant weight loss typically becomes apparent by weeks 4–8. The full effect of the medication usually isn’t realized until patients have been on a therapeutic dose (1.7 mg or 2.4 mg) for several months.

Side effects and management

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most pronounced during dose increases and typically improve as your body adapts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage these symptoms.

More serious but rare side effects include pancreatitis, gallbladder issues, and potential thyroid concerns (semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies, though this hasn’t been confirmed in humans). Your provider should review your complete medical history to identify any contraindications before prescribing.

Compounded semaglutide vs. brand-name

With brand-name Wegovy often facing supply constraints and high out-of-pocket costs, many patients are turning to compounded semaglutide from 503B-compliant pharmacies. Compounded versions contain the same active ingredient but are prepared by specialized pharmacies under FDA oversight.

The key when choosing compounded semaglutide is ensuring your pharmacy is legitimate. Look for 503B registration (which subjects the pharmacy to FDA inspections), third-party purity testing, and a requirement for a valid prescription. At Craft Peptides, we exclusively work with 503B-compliant pharmacies that meet these standards.

Is semaglutide right for you?

Semaglutide is generally indicated for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). However, the decision to start treatment should be made in consultation with a qualified provider who can evaluate your full clinical picture.

Weight loss medications work best as part of a comprehensive approach that includes nutrition guidance, physical activity, and behavioral support. Semaglutide is a powerful tool, but it’s most effective when combined with sustainable lifestyle changes.